Autres langues Lixte Biotechnology Holdings, Inc.

Actions

LIXT

US5393193017

Marché Fermé - Nasdaq Autres places de cotation 22:30:01 25/04/2024			Varia. 5j.	Varia. 1 janv.
3,22 ^USD	-1,83 %		-3,91 %	+37,02 %

23/04	Lixte Biotechnology dépose une déclaration d'enregistrement mixte pour un montant maximum de 50 millions de dollars	MT
27/03	Mise à jour sectorielle : Les actions du secteur de la santé progressent en fin d'après-midi	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Lixte Biotechnology Files Up to $50 Million Mixed Shelf	23/04
Sector Update: Health Care Stocks Advance Late Afternoon	27/03
Top Midday Gainers	27/03
Wall Street Set to Open Higher Wednesday as Investors Eye End-of-Week Economic, Inflation Data	27/03
NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIES	27/03
Lixte Biotechnology Holdings, Inc. Announces Publication of Pre-Clinical Data in the Online Journal	27/03
LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments	21/03
LIXTE Biotechnology Holdings, Inc. Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments	21/03
Lixte Biotechnology Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	19/03
Professor René Bernards to Present New Pre-Clinical Data on LIXTE’s LB-100 at Joint Conference of European and American Associations for Cancer Research	27/02
LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI	26/02
LIXTE Biotechnology Holdings, Inc. Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCI	26/02
First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial	29/01
Lixte Biotechnology Holdings, Inc. Announces Dosing of the First Patient in A Phase 1B/2 Clinical Trial to Assess Whether Adding Lixte?S Lb-100 to Gsk?S Programmed Death Receptor-1 (Pd-1)-Blocking Monoclonal Antibody, Dostarlimab-Gxly, May Enhance the Effectiveness of Immunotherapy in the Treatment of Ovarian Clear Cell Carcinoma	29/01
Top Premarket Decliners	28/11
Lixte Biotechnology : Investor Presentation - November 2023	20/11
LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations	13/11
Lixte Biotechnology Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Certain Common Stock of Lixte Biotechnology Holdings, Inc. are subject to a Lock-Up Agreement Ending on 19-OCT-2023.	19/10/23
Certain Series A Preferred Stock of Lixte Biotechnology Holdings, Inc. are subject to a Lock-Up Agreement Ending on 19-OCT-2023.	19/10/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Lixte Biotechnology Holdings, Inc.

Actions

LIXT

US5393193017

Autres langues

Filtres